Almirall, S.A.

ALM

ES0157097017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 11:39:20 2024-04-16 am EDT			5-day change	1st Jan Change
8.13 ^EUR	-0.85%		-1.15%	-3.44%

Mar. 13	Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	MT
Feb. 19	Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...

Almirall S A : announces a new publication in the British Journal of Dermatology of ILUMETRI®▼ (tildrakizumab) as the first anti-IL23p19 treatment for which 5-year efficacy and safety data are reported from two phase 3 studies

February 09, 2021 at 10:37 am EST

We use our own and third-party cookies for statistical purposes.

You can set your preferences (including rejection) or accept them all. If you need to learn more, please read our Cookie policy

Attachments

Original document
Permalink

Disclaimer

Almirall SA published this content on 09 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 February 2021 15:36:02 UTC.

Latest news about Almirall, S.A.

Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Almirall: share price surges after agreement with Novo Nordisk	Feb. 19	CF
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024	Feb. 19
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	Feb. 19	MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	Feb. 19	CI
Almirall, S.A. Provides Earnings Guidance for the Year 2024	Feb. 19	CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 18	CI
Transcript : Almirall, S.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	Dec. 21	CI
Almirall: messenger RNA alliance with Belgium's etherna	Dec. 12	CF
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	Dec. 12	MT
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	Dec. 12	CI
Certain Shares of Almirall, S.A. are subject to a Lock-Up Agreement Ending on 10-DEC-2023.	Dec. 09	CI
Almirall: share price rises, EU green light for eczema treatment	Nov. 17	CF
European Commission Approves Almirall’s Skin Disease Drug	Nov. 17	MT
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis	Nov. 17	CI
Almirall Teams Up with Absci on AI-designed Dermatological Disease Treatments	Nov. 14	MT
Sector Update: Health Care Stocks Advance Premarket Tuesday	Nov. 14	MT
Absci Enters AI Drug Discovery Pact With Almirall to Develop New Therapies for Dermatological Diseases; Shares Surge Premarket	Nov. 14	MT
Transcript : Almirall, S.A., Nine Months 2023 Earnings Call, Nov 09, 2023	Nov. 09
Almirall, S.A. Revises Earnings Guidance for the Year 2023	Nov. 09	CI
Almirall, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 08	CI
Almirall’s Eczema Drug Shows Clinical Improvements in Adults, Adolescents	23-10-13	MT
Almirall Signs Licensing Deal With EpimAb for Bispecific Antibodies Development	23-10-12	MT

Chart Almirall, S.A.

Duration

Period

More charts

Company Profile

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Sector

Pharmaceuticals

Calendar

2024-05-10 - Annual General Meeting - First Call

More about the company

Income Statement Evolution

More financial data

Ratings for Almirall, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.2 EUR

Average target price

11.28 EUR

Spread / Average Target

+37.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALMIRALL, S.A.	-3.44%	1.83B
ELI LILLY AND COMPANY	+28.11%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.64%	356B
MERCK & CO., INC.	+15.27%	320B
ABBVIE INC.	+5.58%	286B
ASTRAZENECA PLC	+2.75%	213B
NOVARTIS AG	+0.38%	207B
ROCHE HOLDING AG	-9.53%	199B
AMGEN INC.	-8.04%	142B

Other Pharmaceuticals

Almirall, S.A.

Equities

ALM

ES0157097017

Pharmaceuticals

Almirall S A : announces a new publication in the British Journal of Dermatology of ILUMETRI®▼ (tildrakizumab) as the first anti-IL23p19 treatment for which 5-year efficacy and safety data are reported from two phase 3 studies

EPS Revisions